55 articles for Z Shen
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
13
Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.
Peking Union Medical College
26
Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
Institute of Materia Medica
1
Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO).
Zhengzhou University
28
Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Peking Union Medical College
6
Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents.
Zhejiang Academy of Medical Sciences
2
Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPAR .
Peking Union Medical College
42
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Peking Union Medical College
22
Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.
Merck Research Laboratories
23
A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.
Merck Research Laboratories
37
A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.
Merck Research Laboratories
24
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.
TBA
38
Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors.
Merck Research Laboratories
24
Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors.
Merck Research Laboratories
26
Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.
Merck Research Laboratories
46
The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors.
Merck Research Laboratories
33
Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors.
Merck Research Laboratories
62
Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity.
Merck Research Laboratories
19
The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.
Pfizer
25
Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporter.
Wyeth Research
27
Design, Synthesis, and Biological Evaluation of Pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Potent and Orally Available Noncovalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
East China University of Science and Technology
16
TRPM8 and TRPA1 ideal targets for treating cold-induced pain.
Dalian Medical University
63
Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.
University of Arizona
34
Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
University of Illinois at Chicago
4
Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.
Chinese Academy of Medical Sciences&Peking Union Medical College
67
Synthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs).
University of Arizona
4
Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.
Chinese Academy of Medical Sciences&Peking Union Medical College
5
Molecular editing of
National Institute of Pharmaceutical Education and Research (NIPER)
37
Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Bristol Myers Squibb
36
3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships.
Bristol Myers Squibb
72
Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
Bristol Myers Squibb
49
Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.
Bristol Myers Squibb
13
Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3.
Bristol Myers Squibb
34
Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues.
Bristol Myers Squibb
31
Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series.
Bristol Myers Squibb
15
The TosMIC approach to 3-(oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors.
Bristol Myers Squibb
30
Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase.
Bristol Myers Squibb
46
Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Bristol Myers Squibb
21
The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Chinese Academy of Medical Sciences&Peking Union Medical College
2
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.
University of Illinois At Chicago
23
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
University of Illinois At Chicago
15
Development of the "hidden" multifunctional agents for Alzheimer's disease.
Zhejiang Academy of Medical Sciences
19
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
University of Illinois At Chicago
22
Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
Henan University of Traditional Chinese Medicine
8
Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.
Peking Union Medical College
139
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
Merck Sharp & Dohme
63
FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
Saint Joseph'S University
18
Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
Kainos Medicine